Sanofi is reportedly evaluating a potential acquisition of Insmed, whose respiratory drugs and pipeline could strengthen Sanofi’s portfolio ahead of Dupixent’s expected patent expiry. Discussions are ongoing, with no confirmed bid or disclosed terms. Insmed shares rose after the reports, while coverage also noted questions about the price and Sanofi’s ability to fund a deal.
Sanofi outlines timelines for vaccine trial results
Sanofi expects results within about 18 months from Phase III studies of a combined flu-COVID vaccine and an RSV-hMPV program, while pediatric Phase III trials of its PCV21 pneumococcal vaccine are expected to report in 2027. The company also expanded its Phase II acne-vaccine trial to 800 volunteers, with results expected in 2028, and is evaluating an experimental shingles vaccine.
FDA approves Sanofi's Infilbray for Type 3 Gaucher disease
The FDA approved Sanofi’s oral Infilbray for neurological manifestations of Type 3 Gaucher disease. The decision was supported by the Phase 3 LEAP2MONO trial, which showed significant improvement in neurological measures versus enzyme replacement therapy. The medicine is under review in the EU and Japan, and the articles note warnings including suicidal ideation and behavior.
European Commission approves Sanofi's VaxRabeo rabies vaccine
The European Commission approved Sanofi’s VaxRabeo rabies vaccine for pre- and post-exposure prophylaxis across all ages. Studies found immune responses comparable to Sanofi’s existing vaccines and a consistent safety profile. VaxRabeo also offers a five-year shelf life and improved temperature stability, with Sanofi expecting to submit a U.S. application in the fourth quarter of 2026.
Sanofi selected Jacobs as EPCM partner for a new insulin manufacturing facility alongside its Frankfurt campus. The facility will produce multiple insulin products and is intended to strengthen supply reliability. Jacobs will manage design, procurement, construction and commissioning, using existing site infrastructure and advanced manufacturing systems.
Sanofi valuation model puts shares above estimated fair value
Sanofi received European Commission approval for VaxRabeo, a next-generation rabies vaccine for pre- and post-exposure use across all ages, following US FDA approval of Infilbray for Type 3 Gaucher disease. The company also plans an R&D leadership change in January 2027. Shares have risen recently, while a community valuation model estimates they are 19% above fair value.
Sanofi signs drug research and licensing deal with Seawolf
Sanofi and Seawolf Therapeutics signed a multi-target research and exclusive licensing deal to develop treatments for bleeding disorders and other conditions. The agreement is worth up to $1.2 billion in milestone payments, plus tiered royalties. Seawolf also emerged from stealth with $100 million in financing to advance its DNA-based medicines and metabolic disease programme.
Sanofi and Canadian alliance sign Sarclisa coverage letter
Sanofi and Canada’s pan-Canadian Pharmaceutical Alliance signed a Letter of Intent after completing negotiations for public coverage of Sarclisa plus VRd for adults with newly diagnosed multiple myeloma who are ineligible for stem cell transplant. Public access depends on final funding agreements with each province and territory. The agreement follows Health Canada authorization supported by the IMROZ trial.
Sanofi expands its collaboration with Scribe Therapeutics
Sanofi expanded its Scribe Therapeutics collaboration to access the ELXR epigenetic silencing platform, broadening tools for early-stage research. The article also notes a milestone payment to Novavax tied to progress in a Phase III influenza and COVID-19 combination vaccine trial. It describes the moves as part of Sanofi’s partnership-led research and development strategy, while noting uncertainty over future outcomes.
Windward Bio raised $175 million in its IPO and began trading after Sanofi bought an additional $50 million in shares. The biotech is advancing two China-licensed antibody programs for asthma, COPD and other inflammatory diseases. Windward expects Phase 3 asthma results next year and COPD data in 2027, and could owe licensors up to $1.6 billion in milestone payments.
Sanofi received an upgrade from BNP Paribas to Outperform from Neutral, with analysts citing an average 8% upside. Dupixent sales rose 34.8% to €5.7 billion in the third quarter, and management raised its 2026 outlook. The article also discusses Sanofi’s plans ahead of Dupixent’s eventual patent loss, along with risks including declining vaccine sales and expected pricing effects.
Sanofi reports third-quarter results and raises 2026 guidance
Sanofi reported third-quarter 2026 sales of €14.444 billion and net income of €3.021 billion, and raised full-year earnings guidance, forecasting low-teens sales growth and mid-teens business EPS growth at constant exchange rates. The company discontinued its oral STAT6 degrader program and is advancing a Phase 3 flu-COVID combination vaccine for older adults.
Sanofi shares trade above one fair-value estimate after results and guidance
Sanofi shares rose about 20% over the past month after stronger Q3 results and upgraded 2026 guidance. At €84.10, the stock is 16% above Simply Wall St’s popular fair-value estimate of €72.23, though its DCF model estimates fair value at €243.95. Patent expiries and potential pipeline delays remain key risks.
Sanofi discontinues development of its STAT6 degrader SAR448272
Sanofi will discontinue the Phase 1 trial and development of SAR448272, an oral STAT6 degrader partnered with Nurix, ending Nurix’s eligibility for associated future milestones and royalties. Sanofi cited no immediate patient safety concern but has not explained its decision. Nurix’s cash runway guidance remains unchanged, and its broader Sanofi collaboration continues.
Sanofi exercises option on a Recursion development candidate
Recursion reported third-quarter revenue of $18.55 million, beating estimates, driven largely by a $10 million milestone payment from Sanofi. Sanofi exercised its option on a development candidate from their research collaboration, bringing payments received to $144 million; Recursion remains eligible for more than $300 million in additional milestones and double-digit royalties. Sanofi will fund and lead development, with Phase I studies expected in 2027.